Results 11 to 20 of about 25,585 (256)

FB-BEV: BEV Representation from Forward-Backward View Transformations [PDF]

2023 IEEE/CVF International Conference on Computer Vision (ICCV), 2023
Accept to ICCV 2023, camera-ready ...
Li, Zhiqi, Yu, Zhiding, Wang, Wenhai, Anandkumar, Anima, Lu, Tong, Alvarez, Jose M.   +5 more
core   +5 more sources

Theorising, Writing and Ethics: the Production of Ethnography

, 1995
This work brings together some of the leading writers on feminism to discuss all aspects of how they work. Drawing from a range of different areas such as literature, sociology, film, law, TV and history, they explore how feminist research and ...
Skeggs, Bev
core   +7 more sources

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma

Hepatology, EarlyView., 2022
Steatotic HCC can be diagnosed by MRI and forms a pro‐tumor immune microenvironment with high expression of PD‐L1, M2 polarization of macrophages and activation of CAFs, which may be a good target for combined immunotherapy. Abstract Background and Aims Immunotherapy has become the standard‐of‐care treatment for hepatocellular carcinoma (HCC), but its ...
Hiroki Murai, Takahiro Kodama, Kazuki Maesaka, Shoichiro Tange, Daisuke Motooka, Yutaka Suzuki, Yasuyuki Shigematsu, Kentaro Inamura, Yoshihiro Mise, Akio Saiura, Yoshihiro Ono, Yu Takahashi, Yota Kawasaki, Satoshi Iino, Shogo Kobayashi, Masashi Idogawa, Takashi Tokino, Tomomi Hashidate‐Yoshida, Hideo Shindou, Masanori Miyazaki, Yasuharu Imai, Satoshi Tanaka, Eiji Mita, Kazuyoshi Ohkawa, Hayato Hikita, Ryotaro Sakamori, Tomohide Tatsumi, Hidetoshi Eguchi, Eiichi Morii, Tetsuo Takehara   +29 more
wiley   +1 more source

CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma

Cancer Medicine, 2021
Antiangiogenic therapy with bevacizumab (Bev), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is a common treatment for recurrent glioblastoma (GBM), but its survival benefit is limited.
Masahiro Nishikawa, Akihiro Inoue, Takanori Ohnishi, Hajime Yano, Yonehiro Kanemura, Shohei Kohno, Shiro Ohue, Saya Ozaki, Shirabe Matsumoto, Satoshi Suehiro, Yawara Nakamura, Seiji Shigekawa, Hideaki Watanabe, Riko Kitazawa, Junya Tanaka, Takeharu Kunieda   +15 more
doaj   +1 more source

The impact of parental death on the timing of first marriage: Evolutionary versus social explanations (The Netherlands, 1850-1940)

Demographic Research, 2019
Background: This article examines the impact of parental death in childhood, adolescence, and adulthood on male and female age at marriage in the Netherlands in the period 1850-1940.
Matthias Rosenbaum-Feldbrügge, Enrico Debiasi   +1 more
doaj   +1 more source

Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis

BMC Cancer, 2020
Background It is not known what combination of bevacizumab and chemotherapy agents is the best therapeutic regimen. Comparative study results among the efficacies of bevacizumab plus chemotherapy remain controversial in patients with HER2-negative ...
Zhengwu Sun, Xiaoyan Lan, Shizhao Xu, Shen Li, Yalin Xi   +4 more
doaj   +1 more source

To Bev or Not to Bev during Ovarian Cancer Maintenance Therapy?

Cancers, 2023
Background: Maintenance therapy with PARP inhibitors and bevacizumab is approved for ovarian cancer treatment in the first and second line settings, but selecting the optimal sequence is challenging due to restrictions on using the same medication twice.
openaire   +2 more sources

Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map

BMC Cancer, 2023
Background Glioblastoma (GBM) is the most malignant primary tumor in the brain, with poor prognosis and limited effective therapies. Although Bevacizumab (BEV) has shown promise in extending progression-free survival (PFS) treating GBM, there is no ...
Minjie Fu, Zhirui Zhou, Xiao Huang, Zhenchao Chen, Licheng Zhang, Jinsen Zhang, Wei Hua, Ying Mao   +7 more
doaj   +1 more source

Bev Thomas on Woman's Hour. Discusses her debut novel 'A Good Enough Mother'. 12 April 2018, BBC Radio 4 [Starts at 25:00]

, 2019
Bev Thomas is a clinical psychologist. She's written her debut novel 'A Good Enough Mother' about a trauma therapist who is trying to treat a patient who bears a striking resemblance to her own missing child.
Thomas, Bev
core   +4 more sources

Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience

Frontiers in Oncology, 2020
This study aimed to determine the real-world, long-term prognostic impacts, and adverse effects (AEs) of bevacizumab (BEV) in Asian patients with ovarian/tubal/peritoneal cancers.
Pei-Ying Wu, Ya-Min Cheng, Ya-Min Cheng, Meng-Ru Shen, Meng-Ru Shen, Yi-Chun Chen, Yu-Fang Huang, Cheng-Yang Chou   +7 more
doaj   +1 more source